Related Experiment Video
Updated: Dec 17, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.6K
The Research Progress of DPP-4 Inhibitors
Zhi-Gang Sun1,2,3, Zhi-Na Li1, Hai-Liang Zhu2
1Central Laboratory, Linyi Central Hospital, No. 17 Jiankang Road, Linyi 276400, China
Mini Reviews in Medicinal Chemistry
|July 1, 2020
Summary
Dipeptidyl peptidase-4 (DPP-4) inhibitors offer a promising treatment for type 2 diabetes by enhancing glucagon-like peptide-1 (GLP-1) levels. This review covers DPP-4 inhibitor development from 2015-2019, aiding future drug discovery.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia.
- Type 2 DM accounts for the majority of diabetes cases, often leading to severe complications.
- Glucagon-like peptide-1 (GLP-1) is a key hormone regulating glucose homeostasis, degraded by DPP-4.
Purpose of the Study:
- To review the development of dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 DM treatment.
- To summarize advancements in DPP-4 inhibitor research between 2015 and 2019.
- To provide insights for the discovery of novel DPP-4 inhibitors.
Main Methods:
- Literature review of scientific publications and patents.
- Analysis of drug development trends for DPP-4 inhibitors.
- Synthesis of information on efficacy and safety profiles.
Main Results:
- DPP-4 inhibitors represent a significant therapeutic class for type 2 DM.
- The period 2015-2019 saw continued research and development in DPP-4 inhibitor therapies.
- Understanding past developments is crucial for identifying future research directions.
Conclusions:
- DPP-4 inhibitors effectively manage blood glucose by potentiating GLP-1 action.
- The ongoing evolution of DPP-4 inhibitors offers therapeutic benefits for type 2 DM patients.
- This review serves as a valuable resource for future research into novel DPP-4 inhibitors.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
460
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
460
01:24Glucagon-like Receptor Agonists
720
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
720
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
514
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
514
01:06Oral Hypoglycemic Agents: Glinides
485
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
485
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
443
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
443
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.9K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.9K